Navigation Links
Basis for DNA ejection from single phage particles

Studying phage, a primitive class of virus that infects bacteria by injecting its genomic DNA into host cells, researchers have gained insight into the driving force behind this poorly understood injection process, which has been proposed in the past to occur through the release of pressure accumulated within the viral particle itself.

Almost all phages (also known as bacteriophages) are formed of a capsid structure, or head, in which the viral genome is packaged during morphogenesis, and a tail structure that ensures the attachment of the phage to the host bacteria. A common feature of phages is that during infection, only their genome is transferred to the bacterial host's cytoplasm, whereas the capsid and tail remain bound to the cell surface. This situation is very different from that found in most eukaryotic viruses, including those that infect humans, in that the envelope of these viruses fuses with the host plasma membrane so that the genome is delivered without directly contacting the membrane.

Phage nucleic acid transport poses a fascinating biophysical problem: Transport is unidirectional and linear; it concerns a unique molecule the size of which may represent 50 times that of the bacterium. The driving force for DNA transport is still poorly defined. It was hypothesized that the internal pressure built during packaging of the DNA in the phage capsid was responsible for DNA ejection. This pressure results from the condensation of the DNA during morphogenesis ?for example, another group recently showed that the pressure at the final stage of encapsulation for a particular bacteriophage reached a value of 60 atomospheres, which is close to ten times the pressure inside a bottle of champagne. In the new work reported this week, researchers have evaluated whether the energy thus stored is sufficient to permit phage DNA ejection, or only to initiate that process.

The researchers used fluorescently labeled phage DNA to investigate in real
'"/>

Source:Cell Press


Page: 1 2

Related biology news :

1. Fibril Shape Is The Basis Of Prion Strains And Cross-species Prion Infection
2. New type of rejection blocker protects kidneys after transplant
3. Simple sea sponge helps scientists understand tissue rejection
4. Researchers identify genes associated with lung transplant rejection
5. Carnegie Mellon develops non-invasive technique to detect transplant rejection at cellular level
6. Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection
7. Proteins may predict lung transplant rejection
8. Opposing fat metabolism pathways triggered by a single gene
9. Ancient DNA confirms single origin of Malagasy primates
10. No single gene for ageing
11. Natural selection at single gene demonstrated
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Basis for DNA ejection from single phage particles

(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... brain can form insulin-producing cells that mimic those missing ... in the April 26 issue of PLoS Medicine. , ... patients, Seung Kim, MD, PhD, the lead author and ... School of Medicine, said it could lead to new ...
... Chicago have found that a recently discovered biological process known ... in the nucleus -- also occurs near the cell's surface ... of proteins, providing a novel target for the development of ... 2005 issue of the journal Cell, answers a question dating ...
... first field trial of plants genetically tweaked to absorb ... beat out their wild-type counterparts. The results raised hopes ... cleaning up polluted soil. , The new research findings, ... Technology, show that three transgenic lines of the Indian ...
Cached Biology News:Stem cells from brain transformed to produce insulin at Stanford 2Stem cells from brain transformed to produce insulin at Stanford 350-year-old Mystery Solved: Protein Tags Regulate Key Ion Channel 250-year-old Mystery Solved: Protein Tags Regulate Key Ion Channel 3Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 2Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 3Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 4
(Date:9/2/2015)...  Neurotech Pharmaceuticals, Inc., announced today the first ... 2 clinical trial of NT-503 Encapsulated Cell Therapy ... choroidal neovascularization secondary to age related macular degeneration ... growth factor (VEGF) receptor protein continuously produced by ... proof-of-concept study will evaluate NT-503 ECT as a ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 /PRNewswire/ ... today announced the intent of the National Institute of Allergy ... of Health (NIH) within the Department of Health and Human ... be held in the United States ... of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as a ...
(Date:9/2/2015)... ... 02, 2015 , ... The TS5-Q is designed for myriad ... to analysis of athletic performance. Producing high-resolution slow-motion video , the TS5-Q ... process with the naked eye. , Slow motion sequences are commonly seen ...
(Date:9/1/2015)... 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), ... of targeted antiviral therapies, announced today that it will ... Annual Global Investment Conference sponsored by H.C. Wainwright ... The St. Regis Hotel in New York, ... , Chief Executive Officer, will provide an overview of ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... Campbell Alliance, the leading management consulting firm specializing in ... launched a new practice area focused on medical affairs. ... practice enables the firm to specifically target the evolving needs ... firm has done work in the area of medical affairs ...
... OSLO, Norway, June 17 , ... Improve Remission Rates and,Reduce Short-Term Mortality Compared to Previous ... (OSE: CLAVIS) today announces positive final results,from a Phase ... in patients with late-stage acute myeloid leukaemia (AML). In ...
... Nearly 200 Quantitative Immunoassays for Discovery and Validation ... Texas, June 17 Rules-Based Medicine, Incorporated (RBM), ... announced the availability of the most comprehensive collection ... efficacy and efficiency in drug and diagnostic development. ...
Cached Biology Technology:Campbell Alliance Launches New Practice Area Focused on Medical Affairs 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 2Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 3